Gossamer Bio, Inc. cotiza a 9.81 USD y tiene una capitalización bursátil de $60M. En los últimos 12 meses ha facturado $53M con un margen de flujo de caja libre del -353.5%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or …
| Periodo | 2026-11 | 2026-08 | 2026-08 | 2026-05 |
|---|---|---|---|---|
| Real | — | $-8.17 | — | $-16.00 |
| Estimado | $-3.93 | $-9.99 | $-0.12 | $-13.64 |
| Sorpresa | — | +18.2% | — | -17.3% |
| Métrica | GOSS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -352.2% | -38.6% | -313.6% |
| Net Margin | -351.5% | -33.6% | -317.9% |
| FCF Margin | -353.5% | -13.9% | -339.6% |
| ROE | — | -40.4% | — |
| ROA | -98.9% | -32.0% | -66.9% |
| Current Ratio | 2.64 | 2.84 | -0.20 |
| Debt / Equity | — | 0.28 | — |